222: Matt McCarthy | The Race to Stop a Superbug Epidemic

Ethical Challenges

The ethical challenges faced by pharmaceutical companies in antibiotic development are immense. Dr. Matt McCarthy highlights the dilemma where companies prioritize shareholder profits over patient needs, leading to a lack of investment in essential antibiotics 1. He notes that antibiotics, unlike chronic medications, are short-term treatments, making them less profitable 2. This creates a market where incentives are needed to encourage development, yet the ethical implications of such incentives are complex.

I have an ethical mandate to charge as much money as possible for the antibiotics that I make because I am accountable to shareholders and not to patients.

--- Dr. Matt McCarthy

The conversation also touches on the negative public perception of big pharma, especially in light of recent scandals, which complicates efforts to negotiate incentives for antibiotic production 2.

   

Market Dynamics

The dynamics of the drug market significantly hinder antibiotic development, with nationalization of production being one proposed solution. Dr. Matt McCarthy argues that while nationalization might seem appealing, it could stifle innovation and is not a proven success, as seen in England 3. Instead, he suggests that private companies, with their expertise in drug development, should be incentivized to innovate and produce new antibiotics.

We need this pharmaceutical partner that the federal government is very good at investing in scientists who can make these discoveries. But then we need private industry to then develop it.

--- Dr. Matt McCarthy

Access to drugs is another critical issue, with disparities in availability between wealthy and poor regions. Dr. McCarthy emphasizes the importance of addressing these disparities, as even basic drugs like penicillin are hard to access in some areas due to production limitations 4.